Study of the Association Between Hip Fracture and Acid‐Suppressive Drug Use in a UK Primary Care Setting

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Pharmacotherapy

• Publication date

  2014-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/phar.1410PMID 24634193
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk Factors for Falls with Use of Acid-Suppressive Drugs

  2013cited by this paper
• Primary Medical Care in the United Kingdom

  2012influential reference
• Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS)

  2012cited by this paper
• The Relationship Between Proton Pump Inhibitor Use and Longitudinal Change in Bone Mineral Density: A Population-Based From the Canadian Multicentre Osteoporosis Study (CaMos)

  2012cited by this paper
• Lansoprazole

  2012cited by this paper
• Bone health in adult cancer survivorship.

  2012cited by this paper
• Proton Pump Inhibitors and Risk of Fracture: A Systematic Review and Meta-Analysis of Observational Studies

  2011cited by this paper
• Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates.

  2011cited by this paper
• Meta-analysis: risk of fractures with acid-suppressing medication.

  2011cited by this paper
• Body mass index and physical activity in relation to the incidence of hip fracture in postmenopausal women

  2011cited by this paper
• Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.

  2010cited by this paper
• Hip fracture risk in patients with a diagnosis of pernicious anemia.

  2010cited by this paper
• Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study

  2010cited by this paper
• Safety of proton pump inhibitor exposure.

  2010cited by this paper
• The assessment of fracture risk.

  2010cited by this paper
• Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.

  2010cited by this paper
• Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates

  2009cited by this paper
• Incidence and mortality of hip fractures in the United States.

  2009cited by this paper
• The impact of statins, ace inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort

  2009cited by this paper
• Epidemiology of hip fracture in Japan: incidence and risk factors

  2009cited by this paper
• Risk of community‐acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population‐based case–control study

  2009cited by this paper
• Assessment of fracture risk.

  2009cited by this paper
• Acid-suppressive Drugs and Community-acquired Pneumonia

  2009cited by this paper
• American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease.

  2008cited by this paper
• Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults

  2008cited by this paper
• The association between physical activity and osteoporotic fractures: a review of the evidence and implications for future research.

  2008cited by this paper
• Exposure to antiepileptic drugs and the risk of hip fracture: A case‐control study

  2008cited by this paper
• Proton pump-inhibiting drugs, calcium homeostasis, and bone health.

  2008cited by this paper
• Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors

  2008cited by this paper
• Relationship between symptoms, subjective well-being and medication use in gastro-oesophageal reflux disease

  2007cited by this paper
• Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research

  2007cited by this paper
• Long-term proton pump inhibitor therapy and risk of hip fracture.

  2006cited by this paper
• Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture

  2006cited by this paper
• Bone loss and fracture risk associated with cancer therapy.

  2006cited by this paper
• Incidence of Fractures among Epilepsy Patients: A Population‐based Retrospective Cohort Study in the General Practice Research Database

  2005cited by this paper
• Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.

  2005cited by this paper
• Genetic control of susceptibility to osteoporosis.

  2002cited by this paper
• Epidemiology of fractures in England and Wales.

  2001cited by this paper
• Use of nonsteroidal anti-inflammatory drugs and risk of fractures.

  2000cited by this paper
• Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.

  1997cited by this paper
• Erratum to Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders

  1996cited by this paper
• Pantoprazole Review of its Pharmacological Properties and Therapeutic Use in Acid-Related Disorders

  1996cited by this paper
• What does the odds ratio estimate in a case-control study?

  1993cited by this paper
• Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans

  1993cited by this paper
• [Evaluation of unexpected and toxic effects of omeprazole (Mopral) reported to the regional centers of pharmacovigilance during the first 22 postmarketing months].

  1993cited by this paper
• Observation and inference. An introduction to the methods of epidemiology

  1991cited by this paper
• An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium.

  1984cited by this paper

• Bone health, renal outcomes, and iron deficiency anaemia in proton pump inhibitor versus histamine-2 receptor antagonist users: a retrospective cohort study based on TriNetX global collaborative network data

  2025cites this paper
• Fracture Risk Linked to Proton Pump Inhibitors Versus H2 Receptor Antagonists in Autoimmune Rheumatic and Gastrointestinal Disease Patients

  2025cites this paper
• Updating understanding of real-world adverse events associated with omeprazole

  2025cites this paper
• Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density

  2024cites this paper
• Prescriptive Appropriateness: Inhospital Adherence to Proton Pump Inhibitors Deprescription Flow Chart

  2023cites this paper
• Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature

  2021cites this paper
• Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study.

  2020cites this paper
• Magnesium oxide and hip fracture in the elderly: a population-based retrospective cohort analysis

  2020cites this paper
• Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review)

  2020cites this paper
• Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease

  2020cites this paper
• Potential proton pump inhibitor–related adverse effects

  2020cites this paper
• Higher dose but not low dose proton pump inhibitors are associated with increased risk of subsequent hip fractures after first hip fracture: A nationwide observational cohort study

  2019cites this paper
• Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved

  2019influential citation
• Proton pump inhibitors and fracture risk. The HUNT study, Norway

  2019cites this paper
• Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study

  2019cites this paper
• Bone Health in Glomerular Kidney Disease

  2019cites this paper
• Proton pump inhibitors therapy and risk of bone diseases: An update meta‐analysis

  2019cites this paper
• Fracture risk of young adults receiving proton‐pump inhibitors and H2‐receptor antagonists

  2019cites this paper
• Evaluation of Medication Errors at the Transition of Care From an ICU to Non-ICU Location

  2019cites this paper
• Drug-Induced Bone Disorders: A Systematic Review

  2019cites this paper
• The impact of proton pump inhibitors on bone regeneration and implant osseointegration

  2019cites this paper
• Safety assessment of omeprazole use: a review

  2018cites this paper
• Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study

  2018cites this paper
• Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis

  2018cites this paper
• Proton pump inhibitors’ use and risk of hip fracture: a systematic review and meta-analysis

  2018cites this paper
• Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies

  2018influential citation
• Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands

  2017cites this paper
• A Proton Pump Inhibitor in the Reformulation Setting: Bioequivalence and Potential Implications for Long‐Term Safety

  2017cites this paper
• An updated meta-analysis : the effect of proton pump inhibitor on risk of osteoporosis and fracture

  2017influential citation
• Proton pump inhibitors in liver cirrhosis: a review of benefits and harms

  2017cites this paper
• Proton pump inhibitors and osteoporosis

  2016cites this paper
• Risk of seizure associated with use of acid-suppressive drugs: An observational cohort study.

  2016cites this paper
• Role of H2RA and Proton Pump Inhibitor Therapy in Treating Reflux Disease

  2016cites this paper
• Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Española de Patología Digestiva.

  2016cites this paper
• Acid-suppressive medications and risk of fracture: an updated meta-analysis.

  2015cites this paper
• Long‐term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies

  2015cites this paper
• Proton-pump inhibitors and risk of fractures: an update meta-analysis

  2015cites this paper
• The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.

  2015cites this paper
• Proton Pump Inhibitors and Risk of Bone Fractures

  2014cites this paper